Dr. Isabelle Bairati, MD, Ph.D., is a full professor in the Department of Surgery of the Faculty of Medicine at Laval University, a researcher at the CHU Research Centre of Quebec-Laval University (cancer axis), and a researcher at Laval University’s Cancer Research Centre. She carries out her medical activities as a medical consultant to the board of the Capitale-Nationale’s Public Health Department.
Since her postdoctoral training at the Fred Hutchinson Cancer Research Center in Seattle, USA, Dr. Bairati’s research activities have focused on epidemiology, and the clinical epidemiology of cancers. Her research has focused on the study of modifiable risk factors, including nutrition, on the occurrence of cancers, and their prognosis. More specifically, she was the principal investigator of a chemoprevention clinical trial, testing the effectiveness of antioxidant vitamins in preventing the occurrence of second primary cancers in patients with ENT cancer. This clinical trial has shown an adverse effect of high doses of antioxidants in patients with ENT cancer (J Natl Cancer Inst., 2005). During the last 10 years, her research has focused on the study of the prognostic effect of serum, tumor and genetic markers in ENT and ovarian cancers. As a public health physician, she is also interested in the impact of the organization of oncology health services on the prognosis and satisfaction of oncology clients.
6, rue McMahon
Canada G1R 2J6
Data not available
Implementing the role of patient-navigator nurse at a university hospital centre.Journal Article
Can Oncol Nurs J, 16 (1), pp. 11-7, 5-10, 2006, ISSN: 1181-912X.
A prospective study of the insulin-like growth factor axis in relation with prostate cancer in the SU.VI.MAX trial.Journal Article
Cancer Epidemiol Biomarkers Prev, 14 (9), pp. 2269-72, 2005, ISSN: 1055-9965.
Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients.Journal Article
J Clin Oncol, 23 (24), pp. 5805-13, 2005, ISSN: 0732-183X.
Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial.Journal Article
Int J Cancer, 116 (2), pp. 182-6, 2005, ISSN: 0020-7136.
A cosmetic evaluation of breast cancer treatment: a randomized study of radiotherapy boost technique.Journal Article
Int J Radiat Oncol Biol Phys, 62 (5), pp. 1274-82, 2005, ISSN: 0360-3016.
Prognostic significance of lymphovascular invasion in surgically cured rectal carcinoma.Journal Article
Am J Surg, 189 (6), pp. 707-13, 2005, ISSN: 0002-9610.
A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients.Journal Article
J Natl Cancer Inst, 97 (7), pp. 481-8, 2005, ISSN: 0027-8874.
Corridors de services de santé efficients dans le diagnostic et les traitements des femmes avec un cancer du sein : rapport de rechercheBook
Direction régionale de santé publique, [Agence de développement de réseaux locaux de services de santé et de services sociaux Capitale nationale], Beauport, QC, 2005, ISBN: 2-89496-305-X.
Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer.Journal Article
Int J Cancer, 106 (3), pp. 409-15, 2003, ISSN: 0020-7136.
Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer.Journal Article
Urology, 58 (2 Suppl 1), pp. 71-7, 2001, ISSN: 0090-4295.
- Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
- Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2022-06-13
Recently finished projects
- Interaction between environment, diet, physical activities, and sexual habits, in the risk of prostate cancer. Validation of biomarkers to personnalize preventive interventions., Subvention, Société de recherche sur le cancer, Compétition GRePEC (SRC/FRSQ/MDEIE), from 2012-10-01 to 2020-08-31